Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307580 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yao Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, AMP-Activated Protein Kinase Kinases, Proto-Oncogene Proteins p21(ras), Tumor Suppressor Protein p53. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JST SPRING.
Abstract (Originalsprache)
Background
This study aimed to identify the associations between individual KRAS , STK11 , KEAP1 , or TP53 mutations, as well as the comutation status of these genes, and the tumor mutation burden (TMB) with clinical outcomes of lung adenocarcinoma patients treated with immune checkpoint inhibitors (ICIs).
Methods
We collected data from patients with lung adenocarcinoma treated with ICIs from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database between June 2019 and August 2023. The main endpoints were the treatment response and overall survival (OS).
Results
Among 343 patients with lung adenocarcinoma, 61 (18%), 69 (20%), 41 (12%), and 222 (65%) patients had KRAS , STK11 , KEAP1 , and TP53 mutations, respectively. An overall objective response was observed in 94 of 338 patients (28%), including 2 (1%) who achieved a complete response and 92 (27%) who achieved a partial response. Patients with STK11 , KEAP1 , or TP53 mutations had a significantly greater TMB (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan.
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan.
ORCID-Profile: Yao Liang, Yuichi Ando
Förderung
- JST SPRING
Zitieren
APA
Liang, Y., Maeda, O., Kondo, C., Nishida, K., & Ando, Y. (2024). Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0307580
Vancouver
Liang Y, Maeda O, Kondo C, Nishida K, Ando Y. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0307580
BibTeX
@article{Liang2024,
author = {Liang, Yao and Maeda, Osamu and Kondo, Chiaki and Nishida, Kazuki and Ando, Yuichi},
title = {Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307580}
}
EUVIMED